Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis
Publication in refereed journal

Times Cited
Web of Science27WOS source URL (as at 18/10/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractSynergy study with chemotherapeutic agents is a common in vitro strategy in the search for effective cancer therapy. For non-chemotherapeutic agents, efficacious synergistic effects are uncommon. Here, we have examined two non-chemotherapeutic agents for synergistic effects: lovastatin and Tumor Necrosis Factor (TNF)-related apoptosis-inducing ligand (TRAIL) for synergistic effects; on three human malignant glioblastoma cell lines, M059K, M59J, and A172. Cells treated with lovastatin plus TRAIL for 48 h showed 50% apoptotic cell death, whereas TRAIL alone (1,000 ng/ml) did not, suggesting that lovastatin sensitized the glioblastoma cells to TRAIL attack. Cell cycle analysis indicated that lovastatin increased G(0)-G(1) arrest in these cells. Annexin V study demonstrated that apoptosis was the predominant mode of cell death. We conclude that the combination of lovastatin and TRAIL enhances apoptosis synergistically. Moreover, lovastatin sensitized glioblastoma cells to TRAIL, suggesting a new strategy to treat glioblastoma.
All Author(s) ListChan DYL, Chen GG, Poon WS, Liu PC
Journal nameJournal of Neuro-Oncology
Volume Number86
Issue Number3
Pages273 - 283
LanguagesEnglish-United Kingdom
Keywordsapoptosis; glioblastoma; lovastatin; Tumor Necrosis Factor (TNF)-related apoptosis-inducing ligand (TRAIL)
Web of Science Subject CategoriesClinical Neurology; CLINICAL NEUROLOGY; Neurosciences & Neurology; Oncology; ONCOLOGY

Last updated on 2021-18-10 at 23:55